Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Diagnostic Pathology

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.anndiagpath.2017.01.009PMID 28648939
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer

  2014cited by this paper
• Immunohistochemical profile and morphology in triple - negative breast cancers.

  2013cited by this paper
• Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2&agr; Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

  2013cited by this paper
• Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer

  2012cited by this paper
• Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma.

  2010cited by this paper
• Basal-like breast carcinoma: a phenotypically distinct entity.

  2010cited by this paper
• Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country.

  2009cited by this paper
• Basal-like breast carcinoma: from expression profiling to routine practice.

  2009cited by this paper
• Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

  2009cited by this paper
• Triple negative breast cancers: clinical and prognostic implications.

  2009cited by this paper
• Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

  2009cited by this paper
• EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer.

  2009cited by this paper
• How basal are triple‐negative breast cancers?

  2008cited by this paper
• Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters

  2008cited by this paper
• Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer

  2008cited by this paper
• Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients

  2008cited by this paper
• Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA

  2008cited by this paper
• Basal-like breast cancer: a critical review.

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Use of immunohistochemical markers can refine prognosis in triple negative breast cancer

  2007cited by this paper
• Prognostic markers in triple‐negative breast cancer

  2007cited by this paper
• Frequency of the basal‐like phenotype in African breast cancer

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Demystifying basal-like breast carcinomas

  2006cited by this paper
• Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Histological Grading and Prognosis in Breast Cancer

  1957cited by this paper

• Proteomic signatures in triple-negative breast cancer.

  2026cites this paper
• EGFR and AR expression and co-expression in Indian triple-negative breast cancer with patient outcome association.

  2026cites this paper
• Keratin as a Potential Prognostic Biomarker for Breast Cancer Progression: An Evidence-Synthesizing Narrative Review

  2026influential citation
• Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Tumor-Infiltrating Lymphocytes (TILs), for Patients with Triple-Negative Breast Cancer.

  2026cites this paper
• Predictive value of androgen receptor in distant metastasis of triple-negative breast cancer: a retrospective multi-center study

  2025cites this paper
• Prognostic Interplay of Caveolin1 and FOXC1 in Early Nonmetastatic Triple Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

  2025cites this paper
• Targeting the tumor microenvironment in triple-negative breast cancer: Biological insights and therapeutic opportunities.

  2025cites this paper
• Effect of HER2-low expression on the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer

  2025influential citation
• Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy

  2024cites this paper
• Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses

  2024cites this paper
• Molecular Profiling of a Triple-negative Breast Cancer Cohort in India for EGFR and AR expression analyzed for patient outcomes showed a distinct subset of cellular co-expression

  2024cites this paper
• Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis

  2024cites this paper
• Increase of KLK7, cytokeratin 5/6, and elafin expression in head and neck squamous cell carcinoma compared with lung squamous cell carcinoma

  2024cites this paper
• Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review

  2023cites this paper
• Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients

  2023cites this paper
• Prognostic and predictive value of a novel 100-point scale in patients with T1–2N0M0 breast cancer

  2023cites this paper
• FOXC1 and SOX10 in Estrogen Receptor-Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction.

  2023cites this paper
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?

  2023cites this paper
• Prognostic and Predictive Biomarkers in Familial Breast Cancer

  2023cites this paper
• Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis

  2023cites this paper
• PARP1, BRCA1 and androgen receptor expression in triple-negative breast cancer patients treated with neoadjuvant chemotherapy

  2022cites this paper
• Computer-Aided Diagnosis Parameters of Invasive Carcinoma of No Special Type on 3T MRI: Correlation with Pathologic Immunohistochemical Markers.

  2022cites this paper
• Cytokeratin Expression Pattern in Human Endometrial Carcinomas and Lymph Nodes Micrometastasis: a Mini-review

  2022cites this paper
• Antitumor Activities in Mouse Xenograft Models of Canine Mammary Gland Tumor by Defucosylated Mouse-Dog Chimeric Anti-Epidermal Growth Factor Receptor Antibody (E134Bf)

  2022cites this paper
• Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker

  2022cites this paper
• Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells

  2022cites this paper
• Determining the Expressions of Cytokeratin 5/6 by Immunohistochemistry in Basal Like Triple Negative Breast Carcinoma and Its Correlation with Histomorphological Grade

  2021cites this paper
• Computer-Aided Diagnosis Parameters of Invasive Carcinoma of No Special Type on 3T MRI: Correlation with Pathologic Immunohistochemical Markers

  2021cites this paper
• The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine

  2021cites this paper
• Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer

  2021cites this paper
• Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer

  2021cites this paper
• Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer

  2021cites this paper
• Cortactin and HER2 as potential markers for dural-targeted therapy in advanced gastric cancer

  2021cites this paper
• Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications

  2021cites this paper
• Proteomics and its applications in breast cancer.

  2021cites this paper
• Hubungan antara ekspresi Epidermal Growth Factor Receptor (EGFR) dengan berbagai parameter klinik dan patologis Triple Negative Breast Cancer (TNBC) di RSUP Sanglah, Bali, Indonesia

  2021influential citation
• Triple-negative mammary carcinoma in two male dogs

  2020cites this paper
• Basal-Like Subgroup is Associated with Younger Age, Increased Expression of Androgen Receptor, and Worse Prognosis, while Non-basal-like Subtype is Associated with Higher BMI in Triple-Negative Breast Cancer Patients

  2020cites this paper
• Triple-negative breast cancer: promising prognostic biomarkers currently in development

  2020cites this paper
• Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer

  2020cites this paper
• The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients

  2020cites this paper
• Changes in Cytokeratin 18 during Neoadjuvant Chemotherapy of Breast Cancer: A Prospective Study

  2020cites this paper
• Breast cancer cutaneous metastases are associated to uMUC1 and sialyl Lewis x and to highly malignant primary tumors.

  2020cites this paper
• G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer

  2020cites this paper
• Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer

  2020cites this paper
• Cytokeratin 5 alters β-catenin dynamics in breast cancer cells

  2020cites this paper
• The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

  2019cites this paper
• Novel Prognostic Markers in Triple-Negative Breast Cancer Discovered by MALDI-Mass Spectrometry Imaging

  2019cites this paper
• Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs

  2019cites this paper
• Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer

  2019cites this paper
• Antitumor and antimetastatic effects of PLA2-BthTX-II from Bothrops jararacussu venom on human breast cancer cells.

  2019cites this paper
• Identification of mechanisms of acquired resistance to taxanes in triple negative breast cancer using patient-derived xenografts: a step closer to clinics

  2018cites this paper
• Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer

  2018cites this paper
• EGFR Immunoexpression in Laryngeal Squamous Cell Carcinoma

  2017cites this paper
• Protein biomarkers of feline mammary carcinoma

  year unknowncites this paper